KCNH2 and acquired long QT syndrome: hERG continues to be of intense pharmacological interest due to the wide variety of cardiac and noncardiac drugs that block the channel with the potential to cause acquired long QT syndrome (aLQTS) and torsades de pointes (TdP) arrhythmia, which can lead to sudden cardiac death (3, 4).